SciSparc's NeuroThera Labs Initiates Phase IIb Clinical Study To Evaluate SCI-110 Drug Candidate To Treat Tourette Syndrome
SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel
A company is testing a new medicine to help people with Tourette Syndrome—moving from smaller tests to a bigger test with more patients. When a drug company reaches this stage, it means their medicine showed promise, so investors watch to see if the bigger test goes well.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.